LOS ANGELES, Oct. 22, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of...
Hence then, the article about armata pharmaceuticals highlights positive results from phase 2a disarm study of its staphylococcus aureus bacteriophage cocktail ap sa02 in late breaking oral presentation at idweek 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™ )
Also on site :
- Trump’s Christmas Eve calls with children asking about Santa’s whereabouts are steeped in partisan politics
- Update: Flood watch affecting 5 Freeway north of LA until early Friday evening caused by persistent downpours
- Ukraine-Russia war latest: Zelensky awaits Putin response to new peace plan while Christmas Eve blast kills 3 in Moscow